

the staff of the Institute and discussions concerning Institute programs.

*Place:* National Institutes of Health, 5635 Fishers Lane, Terrace Level Conference Center, Bethesda, MD 20892.

*Closed* 1 p.m. to Adjournment.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 5635 Fishers Lane, Terrace Level Conference Center, Bethesda, MD 20892.

*Contact Person:* Andrew P. Mariani, PhD, Executive Secretary, National Advisory Eye Council, National Eye Institute, National Institutes of Health, 301-451-2020, [amp@nei.nih.gov](mailto:amp@nei.nih.gov).

Any person interested may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: <http://www.nei.nih.gov>, where an agenda and any additional information will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS)

Dated: April 25, 2011.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2011-10478 Filed 4-29-11; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Research Resources; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Center for Research Resources Special Emphasis Panel; STRB.

*Date:* May 26, 2011.

*Time:* 1:30 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Democracy Blvd., Bethesda, MD 20892.

*Contact Person:* Barbara J. Nelson, PhD, Scientific Review Officer, Office Of Review, National Center For Research Resources, 6701 Democracy Blvd. Room 1080, 1 Democracy Plaza, Bethesda, MD 20892, 301-435-0806, [nelsonbj@mail.nih.gov](mailto:nelsonbj@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research; 93.371, Biomedical Technology; 93.389, Research Infrastructure, 93.306, 93.333; 93.702, ARRA Related Construction Awards, National Institutes of Health, HHS)

Dated: April 25, 2011.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2011-10471 Filed 4-29-11; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel.

*Date:* May 19, 2011.

*Time:* 12 p.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge 6700, 6700B Rockledge Drive, Bethesda, MD 20817, (Telephone Conference Call).

*Contact Person:* Frank S. DeSilva, PhD, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892-7616, 301-594-1009, [fdesilva@niaid.nih.gov](mailto:fdesilva@niaid.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: April 25, 2011.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2011-10469 Filed 4-29-11; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (240) 276-1243.

#### Project—RECOVERY: Increasing Adoption of Patient Centered Behavioral Health Research by Primary and Behavioral Health Providers and Systems—NEW

SAMHSA's Center for Behavioral Health Statistics and Quality (CBHSQ) will conduct a study to evaluate the impact of different strategies for disseminating and promoting the adoption of patient-centered health research results among behavioral health and primary care providers and organizations that are responsible for delivering behavioral health services. Data collected by this study will allow CBHSQ to document and examine the impact of two dissemination strategies on the decision to adopt patient-centered health research; specifically, motivational interviewing and trauma-focused cognitive behavioral therapy. These data will also allow for an examination of contextual factors, both organizational and individual, that influence this decision to adopt an evidence-based behavioral health intervention. Ultimately, data collected by this study will inform those who hope to improve the effectiveness of dissemination strategies aimed at increasing the adoption of patient-centered behavioral health interventions by identifying facilitators and barriers to the adoption process.

Data collection activities involve the administration of five separate surveys (a baseline survey, a followup survey, and three dissemination evaluation surveys) to individuals typically involved in the decisionmaking process

pertaining to the adoption of new behavioral interventions at 40 community health organizations and 40 community behavioral health organizations across the United States. Enrolled organizations will submit their

responses for all surveys via Qualtrics, a third-party, online Web-based survey platform.

The estimated burden for data collection is 940 hours across a total of 400 participants. Using median hourly wage estimates reported by the Bureau

of Labor Statistics, May 2009 National Occupational Employment and Wage Estimates, and a loading rate of 25%, the estimated total cost to respondents is \$63,057.04. A breakdown of these estimates is presented in Table 1 below.

TABLE 1—ESTIMATED BURDEN FOR DATA COLLECTION

Form name	Number of respondents	Number of responses per respondent	Hours per response	Total hour burden
<b>Health Center Directors:</b>				
Baseline Survey, Director Version .....	100	1	0.50	50
Followup Survey, Director Version .....	100	2	0.50	100
Dissemination Evaluation Survey of the Packets .....	100	1	0.17	17
Dissemination Evaluation Survey of the Training Webinar .....	50	1	0.17	8.5
Dissemination Evaluation Survey of the Coaching Webinar .....	50	1	0.17	8.5
Director Subtotal .....	100	.....	.....	184
<b>Health Center Administrators:</b>				
Baseline Survey, Staff Version .....	100	1	0.50	50
Followup Survey, Staff Version .....	100	2	0.50	100
TA Evaluation Survey of the Packets .....	100	1	0.17	17
TA Evaluation Survey of the Training Webinar .....	50	1	0.17	8.5
TA Evaluation Survey of the Coaching Webinar .....	50	1	0.17	8.5
Administrator Subtotal .....	100	.....	.....	184
<b>Practitioners:</b>				
Baseline Survey, Staff Version .....	300	1	0.50	150
Followup Survey, Staff Version .....	300	2	0.50	300
TA Evaluation Survey of the Packets .....	300	1	0.17	51
TA Evaluation Survey of the Training Webinar .....	150	1	0.17	25.5
TA Evaluation Survey of the Coaching Webinar .....	150	1	0.17	25.5
Practitioner Subtotal .....	300	.....	.....	552
<b>Total</b> .....	<b>500</b>	.....	.....	<b>920</b>

Written comments and recommendations concerning the proposed information collection should be sent by June 1, 2011 to: SAMHSA Desk Officer, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503; due to potential delays in OMB's receipt and processing of mail sent through the U.S. Postal Service, respondents are encouraged to submit comments by fax to: 202-395-7285.

Dated: April 20, 2011.

**Elaine Parry,**

*Director, Office of Management, Technology and Operations.*

[FR Doc. 2011-10519 Filed 4-29-11; 8:45 am]

**BILLING CODE 4162-20-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Current List of Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services (HHS) notifies Federal agencies of the Laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the **Federal Register** on April 11, 1988 (53 FR 11970), and subsequently revised in the **Federal Register** on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10,

2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809).

A notice listing all currently certified Laboratories and Instrumented Initial Testing Facilities (IITF) is published in the **Federal Register** during the first week of each month. If any Laboratory/IITF's certification is suspended or revoked, the Laboratory/IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any Laboratory/IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at <http://www.workplace.samhsa.gov> and <http://www.drugfreeworkplace.gov>.

**FOR FURTHER INFORMATION CONTACT:** Mrs. Giselle Hersh, Division of Workplace Programs, SAMHSA/CSAP, Room 2-1042, One Choke Cherry Road, Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).

**SUPPLEMENTARY INFORMATION:** The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Public